Pierre Fabre to commercialize and distribute the first approved allogeneic T-cell immunotherapy in Europe Following transfer of the European Commission marketing authorization from Atara Biotherapeutics, Pierre Fabre is to lead launch and commercialization activities for  Ebvallo® (tabelecleucel) in Europe The french group Pierre Fabre and Atara Biotherapeutics, a californian biotech…..